FR3078535B1 - Composition vaccinale anti-pd-l1 - Google Patents

Composition vaccinale anti-pd-l1 Download PDF

Info

Publication number
FR3078535B1
FR3078535B1 FR1851895A FR1851895A FR3078535B1 FR 3078535 B1 FR3078535 B1 FR 3078535B1 FR 1851895 A FR1851895 A FR 1851895A FR 1851895 A FR1851895 A FR 1851895A FR 3078535 B1 FR3078535 B1 FR 3078535B1
Authority
FR
France
Prior art keywords
amino acid
sequence
protein
acid residues
chosen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1851895A
Other languages
English (en)
Other versions
FR3078535A1 (fr
Inventor
Lucille Desallais
Jean-Pierre Salles
Jean-Francois Zagury
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PEPTINOV Sas
CNAM Conservatoire National des Arts et Metiers
Original Assignee
PEPTINOV Sas
CNAM Conservatoire National des Arts et Metiers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1851895A priority Critical patent/FR3078535B1/fr
Application filed by PEPTINOV Sas, CNAM Conservatoire National des Arts et Metiers filed Critical PEPTINOV Sas
Priority to JP2020570637A priority patent/JP7560365B2/ja
Priority to US16/978,953 priority patent/US20210395368A1/en
Priority to PCT/EP2019/055463 priority patent/WO2019170686A1/fr
Priority to EP19714323.3A priority patent/EP3762402A1/fr
Priority to CN201980029949.5A priority patent/CN112739711A/zh
Publication of FR3078535A1 publication Critical patent/FR3078535A1/fr
Application granted granted Critical
Publication of FR3078535B1 publication Critical patent/FR3078535B1/fr
Priority to JP2024023145A priority patent/JP2024077635A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne un polypeptide comprenant, ou constitué de : - une première séquence constituée d'au moins 8 résidus d'acides aminés contigus choisis au sein de la séquence s'étendant des résidus d'acides aminés 55 à 67 de la protéine PD-L1 et d'au plus 30 résidus d'acides aminés contigus choisis au sein de la séquence complète de la protéine PD-L1 ; et/ou - une deuxième séquence constituée d'au moins 8 résidus d'acides aminés contigus choisis au sein de la séquence s'étendant des résidus d'acides aminés 85 à 101 de la protéine PD-L1 et d'au plus 30 résidus d'acides aminés contigus choisis au sein de la séquence complète de la protéine PD-L1 ; et/ou - une troisième séquence constituée d'au moins 8 résidus d'acides aminés contigus choisis au sein de la séquence s'étendant des résidus d'acides aminés 111 à 127 de la protéine PD-L1 et d'au plus 30 résidus d'acides aminés contigus choisis au sein de la séquence complète de la protéine PD-L1 ; et/ou - une quatrième séquence constituée d'au moins 8 résidus d'acides aminés contigus choisis au sein de la séquence s'étendant des résidus d'acides aminés 138 à 156 de la protéine PD-L1 et d'au plus 30 résidus d'acides aminés contigus choisis au sein de la séquence complète de la protéine PD-L1 ; et/ou - une cinquième séquence constituée d'au moins 8 résidus d'acides aminés contigus choisis au sein de la séquence s'étendant des résidus d'acides aminés 208 à 223 de la protéine PD-L1 et d'au plus 30 résidus d'acides aminés contigus choisis au sein de la séquence complète de la protéine PD-L1.
FR1851895A 2018-03-05 2018-03-05 Composition vaccinale anti-pd-l1 Active FR3078535B1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
FR1851895A FR3078535B1 (fr) 2018-03-05 2018-03-05 Composition vaccinale anti-pd-l1
US16/978,953 US20210395368A1 (en) 2018-03-05 2019-03-05 Anti-pd-1 vaccine composition
PCT/EP2019/055463 WO2019170686A1 (fr) 2018-03-05 2019-03-05 Composition vaccinale anti-pd-l1
EP19714323.3A EP3762402A1 (fr) 2018-03-05 2019-03-05 Composition vaccinale anti-pd-l1
JP2020570637A JP7560365B2 (ja) 2018-03-05 2019-03-05 抗ｐｄ－ｌ１ワクチン組成物
CN201980029949.5A CN112739711A (zh) 2018-03-05 2019-03-05 抗pd-l1疫苗组合物
JP2024023145A JP2024077635A (ja) 2018-03-05 2024-02-19 抗ｐｄ－ｌ１ワクチン組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1851895A FR3078535B1 (fr) 2018-03-05 2018-03-05 Composition vaccinale anti-pd-l1
FR1851895 2018-03-05

Publications (2)

Publication Number Publication Date
FR3078535A1 FR3078535A1 (fr) 2019-09-06
FR3078535B1 true FR3078535B1 (fr) 2024-02-09

Family

ID=63079997

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1851895A Active FR3078535B1 (fr) 2018-03-05 2018-03-05 Composition vaccinale anti-pd-l1

Country Status (6)

Country Link
US (1) US20210395368A1 (fr)
EP (1) EP3762402A1 (fr)
JP (2) JP7560365B2 (fr)
CN (1) CN112739711A (fr)
FR (1) FR3078535B1 (fr)
WO (1) WO2019170686A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022005044A2 (pt) * 2019-09-17 2022-07-05 Ohio State Innovation Foundation Peptídeo quimérico, peptídeo sintético, composição farmacêutica, anticorpo, método de tratamento
EP3845556A1 (fr) * 2019-12-31 2021-07-07 Peptinov SAS Conjugue immunogene destine a induire une reponse immunitaire dirigee contre l interleukine-6
CN112745384A (zh) * 2021-01-15 2021-05-04 新乡学院 猪pd-l14qn-gf表位多肽及其应用
CN113072620B (zh) * 2021-04-26 2022-07-05 南通大学 一种具有镇痛活性的pd-1靶向肽、其合成方法及其应用
WO2024048418A1 (fr) * 2022-08-29 2024-03-07 国立大学法人北海道大学 Anticorps anti-pd-l1 pour la détection de pd-l1

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0026334D0 (en) * 2000-10-27 2000-12-13 Smithkline Beecham Biolog Vaccine
EP1751186A2 (fr) 2004-06-02 2007-02-14 Cytos Biotechnology AG Conjugues entraineurs des peptides du tnf
US8703147B2 (en) * 2007-11-05 2014-04-22 The Walter And Eliza Hall Institute Of Medical Research Methods and compositions for treating and preventing malaria (2)
US9637532B2 (en) * 2013-07-12 2017-05-02 Vlp Therapeutics, Llc Virus like particle comprising PD-1 antigen or PD-1 ligand antigen
EP3092495B1 (fr) * 2014-01-06 2020-11-25 Expression Pathology, Inc. Dosage srm pour pd-l1
JP6824154B2 (ja) 2014-08-08 2021-02-03 ブイエルピー・セラピューティクス・リミテッド・ライアビリティ・カンパニーＶＬＰ Ｔｈｅｒａｐｅｕｔｉｃｓ， ＬＬＣ 修飾エンベロープタンパク質ｅ３を含むウイルス様粒子
WO2016160792A1 (fr) * 2015-03-30 2016-10-06 Stcube & Co., Inc. Anticorps spécifiques de la protéine pd-l1 glycosylée et leurs procédés d'utilisation
WO2017005670A1 (fr) * 2015-07-04 2017-01-12 Evaxion Biotech Aps Protéines et acides nucléiques utiles dans des vaccins ciblant pseudomonas aeruginosa
KR102418372B1 (ko) * 2016-03-29 2022-07-08 주식회사 에스티큐브 글리코실화된 pd-l1에 특이적인 이중 기능 항체 및 이의 사용 방법
EP3446119A1 (fr) * 2016-04-18 2019-02-27 The Broad Institute Inc. Prédiction améliorée d'épitope hla
WO2017211886A1 (fr) 2016-06-07 2017-12-14 Deutsches Krebsforschungszentrum Amélioration de l'immunogénicité des peptides l2 de hpv
WO2017216384A1 (fr) * 2016-06-17 2017-12-21 Evaxion Biotech Aps Vaccination ciblant ichthyophthirius multifiliis

Also Published As

Publication number Publication date
JP2024077635A (ja) 2024-06-07
EP3762402A1 (fr) 2021-01-13
US20210395368A1 (en) 2021-12-23
FR3078535A1 (fr) 2019-09-06
WO2019170686A1 (fr) 2019-09-12
JP2021517472A (ja) 2021-07-26
JP7560365B2 (ja) 2024-10-02
CN112739711A (zh) 2021-04-30

Similar Documents

Publication Publication Date Title
FR3078535B1 (fr) Composition vaccinale anti-pd-l1
JP2019532996A5 (fr)
TR200202254T2 (tr) IL-18 Kaynaklı rahatsızlıkların tedavisinde faydalı rekombinant IL-18 antagonistleri.
EA200800159A1 (ru) РЕКОМБИНАНТНЫЕ МУТАНТЫ ИНТЕРФЕРОНА α2 (IFNα2)
NO20070296L (no) Oligomere peptider og deres anvendelse for behandling av HIV infeksjoner
WO2012046061A3 (fr) Antigènes de clostridium difficile
ATE489462T1 (de) Antimikrobielles polypeptid und nutzung davon
JOP20210298A1 (ar) طرق وتركيبات للوقاية من مرض السكري من النوع الأول
DK0690721T3 (da) Behandling af Mycobakterielle sygdomme ved indgivelse af baktericidt/permeabilitets-forøgende proteinprodukter
WO2013150309A8 (fr) Antigènes de clostridium difficile
PL415888A1 (pl) Sposób wytwarzania insuliny i jej pochodnych oraz peptyd hybrydowy stosowany w tym sposobie
MX2020013296A (es) Composiciones que contienen inhibidor de proteasa recombinante, metodos para producir las mismas y usos de las mismas.
WO2007041285A3 (fr) Complexes de fractions inactivees de pepsines et de proteines de choc thermique
EP4272751A3 (fr) Analogues de compstatine et leurs utilisations médicales
ATE175119T1 (de) Vakzine gegen immunodefizienz-virus der katze (kiv)
EP4361177A3 (fr) Compositions de protéines de fusion recombinées de neuréguline-1 humaine (nrg-1) et procédés d'utilisation associés
WO2003070176A3 (fr) Defensines modifiees et utilisations de ces dernieres
WO2004112820A3 (fr) Peptides et peptidomimetiques activite immunomodulatrice, anti-inflammatoire et antivirale
ATE540971T1 (de) Proteinkinase-c-inhibitoren zur prävention von insulinresistenz und typ-2-diabetes
NO20060675L (no) Forbedrede, rekombinante, humane interferon-beta-lb-polypeptider
HUP0401732A2 (hu) Kopolimerek használata aktív szerként peptidet és fehérjét tartalmazó galenikus formák előállításához
DE60323634D1 (de) Nichtimmunsuppressive immunogene oder vakzinzusammensetzung enthaltend ein mutiertes e7-protein vom humanen papilloma-virus hpv-16
MX2022003531A (es) Polipeptidos de fusion dap10/dap12.
FR3001729B1 (fr) Mutants du facteur x
DK1504036T3 (da) Toxinrelaterede fragmenter af antistoffer med antimikrobiel og antiviral aktivitet

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20190906

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7